Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
Company is Entering Initial Process to Test the Efficacy of a Unique
IVIg as a New and Advanced Malignant Melanoma Treatment Option
Gammacan International (OTC BB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that it
is considering an additional clinical trial to demonstrate clinical
efficacy of hyperimmune intravenous immunoglobulin (IVIg), sourced
from a specific population, for treating Melanoma, a common and
serious skin cancer. The Company is presently in a Phase II clinical
trial utilizing its GCAN - 101 for the treatment of metastatic
melanoma, prostate and colon cancers.
Although melanoma accounts for only 4% of all skin cancers, it
accounts for more than 70% of all skin cancer deaths and the patient
population is steadily increasing. The Melanoma Research Foundation
noted, "No significant advances in medical therapies (or survival) for
patients with advanced melanoma have occurred in the past 30 years".
"We believe that the existing research results regarding the use
of IVIG for treatment of Melanoma provide sufficient incentive to
advance to a clinical stage the efficacy of IVIg sourced from a
specific population for the treatment of Malignant Melanoma," stated
Vered Caplan, CEO.
"Expanding our pipeline of IVIG-based therapies and targeting
specific cancers where little therapeutic benefit has been seen is key
to the Company's growth and to patients suffering from such
devastating diseases," Caplan concluded.
About Gammacan:
Gammacan is focusing on the commercialization of a revolutionary
anti-cancer immunotherapy that the Company believes will be proven to
be effective in reducing the metastatic spread of a wide range of
cancers. Gammacan's proposed treatment is based on IVIG, a safe,
relatively non-toxic human plasma-based product, currently used to
treat a variety of immune deficiencies and autoimmune diseases. It
works by strengthening the patient's immune system. Many experts
currently view immunotherapy as a future alternative to today's
standard chemotherapy. Approximately twenty companies produce IVIG,
and annual worldwide sales are currently in excess of 50 metric tones
with an estimated value in excess of 1.5 billion USD. IVIG is commonly
used to treat certain autoimmune diseases and blood disorders and to
replace the antibodies in people who are unable to produce them. For
more information about Gammacan visit www.gammacan.com or call the
company's headquarters in Givat Shmuel, Israel at 972 3 5774475.
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, inability to hire appropriate staff to develop the
technology, unforeseen technical difficulties in developing the
technology, inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early stage medical
research and development companies filed with the SEC on Edgar.